Entrada Therapeutics Strengthens Leadership Team with Key Appointments
Industry Veterans to Join as Chief Medical Officer and Chief Financial Officer
BOSTON, Mass., December 8, 2020 – Entrada Therapeutics, a privately-held biotechnology company dedicated to transforming the treatment of devastating diseases using intracellular biologics, today announced the appointments of Nerissa Kreher, M.D., as Chief Medical Officer and Kory Wentworth as Chief Financial Officer.
Dr. Kreher, a physician executive with a 15-year record of driving growth at start-ups and larger biotech/pharma companies, comes to Entrada after building clinical and regulatory strategy as Chief Medical Officer at both AVROBIO and Tiburio Therapeutics. Previously, Dr. Kreher was Global Head of Clinical and Medical Affairs at Zafgen, and has held positions of increasing responsibility at EMD Serono, Genzyme, Enobia/Alexion and Shire Pharmaceuticals. She is a board-certified pediatric endocrinologist and began her career as Chief Resident and then attending physician at the Riley Hospital for Children in Indianapolis, Indiana.
“I’ve spent my career helping companies bring new therapies to underserved patient populations,” said Dr. Kreher. “I’m thrilled to join the Entrada team, and to help the company advance a growing and promising pipeline of programs targeting diseases where no adequate treatments for patients exist.”
Mr. Wentworth joins Entrada with 19 years of public accounting and global biopharmaceutical experience. Most recently serving as Vice President, Finance and Treasurer, Principal Accounting Officer at bluebird bio, Mr. Wentworth built a global finance team to support operational expansion, commercial product launches, equity financing and strategic collaboration arrangements. Prior to joining bluebird bio, Mr. Wentworth served as Executive Director and Corporate Controller for Alexion Pharmaceuticals and has held positions of increasing responsibility at PricewaterhouseCoopers LLP, KPMG and Arthur Andersen.
“Entrada is leading the field of intracellular biologics and developing an exciting portfolio,” said Mr. Wentworth. “I look forward to working with the team to shape the Company’s capital formation strategy and build the finance function.”
"We are delighted to have two extraordinarily high caliber executives stepping into leadership roles at Entrada,” said Dipal Doshi, President and Chief Executive Officer. “Nerissa is ideally suited to serve as our Chief Medical Officer given her experience across a wide range of therapeutic areas and Kory brings a proven ability to lead the development of the finance organization. Both Nerissa and Kory are joining Entrada at an exciting point in our Company’s growth trajectory and we look forward to having their leadership on our executive team.”
About Entrada Therapeutics
Entrada Therapeutics’ mission is to treat devastating diseases by developing intracellular biologics. Using its proprietary EEV™ platform, Entrada is creating a diverse pipeline of oligonucleotide, enzyme, protein and peptide programs to efficiently engage intracellular disease targets across multiple therapeutic areas. The Company’s novel approach addresses current challenges associated with both large and small molecule therapeutics and represents a fundamental advancement in the field of intracellular biologics. Entrada is backed by 5AM Ventures, MPM Capital, Roche Venture Fund, MRL Ventures Fund and Agent Capital. For more information, please visit www.entradatx.com.
Entrada Therapeutics, Inc.